Tecentriq
Also known as: Atezolizumab
Pd-l1 may be expressed on tumor cells and/or tumor infiltrated immune cells and may contribute to the inhibition of anti-tumor immune responses in tumor microenvironment. The binding of pd-l1 to T cells showed that pd-1 and B7.1 receptors and antigen presentation showed that the cells inhibited the activity of cytotoxic T cells, t-cell proliferation and cytokine production. Atjuzumab is a monoclonal antibody that binds to pd-l1 and blocks its interaction with pd-1 and B7.1 receptors. This release of pd-l1 / pd-1 mediated inhibition of immune responses, including activation of anti-tumor immune responses, does not induce antibody dependent cytotoxicity. In the homologous mouse tumor model, inhibition of pd-l1 activity leads to reduced tumor growth.
| Payment & Shipping Terms | Supply Capacity | ||
|---|---|---|---|
| Payment Terms: | T/T, WU | Production Capacity: | 1kg/year |
| Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
| Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Tecentriq
CAS: 1380723-44-3
Pharmacological action and mechanism
Pd-l1 may be expressed on tumor cells and/or tumor infiltrated immune cells and may contribute to the inhibition of anti-tumor immune responses in tumor microenvironment. The binding of pd-l1 to T cells showed that pd-1 and B7.1 receptors and antigen presentation showed that the cells inhibited the activity of cytotoxic T cells, t-cell proliferation and cytokine production. Atjuzumab is a monoclonal antibody that binds to pd-l1 and blocks its interaction with pd-1 and B7.1 receptors. This release of pd-l1 / pd-1 mediated inhibition of immune responses, including activation of anti-tumor immune responses, does not induce antibody dependent cytotoxicity. In the homologous mouse tumor model, inhibition of pd-l1 activity leads to reduced tumor growth.
We can customize according to customer's requirement
if you have any question pls mail us or call us
| CAS Number | 1380723-44-3 |
|---|---|
| Place of Origin | Zhejiang,China (Mainland) |
| Name | Tecentriq |
| Name 1 | Atezolizumab |
| CAS | 1380723-44-3 |
Send an inquiry for Tecentriq
Related products
1-Bromo-3-chloro-2-methylpropane
Application:Used as pharmaceutical intermediates
1-benzyl-2-phenyl-1H-imidazole
Contact MOSINTER for product specifications and supply information.
10-Hydroxycamptothecin
Exemestane is an irreversible steroidal aromatase inhibitors, has similar structure with its substrate,natural androstenedione. And it is the pseudo substrate of aromatase . The inhibition of aromatase to estrogen deprivation is a effective method in the treatment of postmenopausal women with hormone dependent breast cancer.
2-Chlorophenothiazine
Application:Chlorpromazine hydrochloride used as drug intermediates; Pharmaceutical intermediates for the preparation of chlorpromazine, perphenazine.
3-Dimethylamino-2-methylpropyl Chloride Hydrochloride
Application:Used as pharmaceutical intermediates
3-Dimethylaminopropylchloride Hydrochloride
1. Used for synthesis of chlorpromazine, doxepin hydrochloride, chlorprothixene medicine, etc
3-Ethyl-4-methyl-3-pyrrolin-2-one
3-Ethyl-4-methyl-3-pyrrolin-2-one, a five-membered α,β-unsaturated lactam derivative, has various applications in medicinal chemistry. It can be synthesized by employing following as starting materials:[1] • allylamine, via palladium(II)-assisted cyclization • 4-methoxybenzylamine, via a ring-closing-metathesis strategy • 3-ethyl-1-(4-methoxybenzyl)-4-methyl-1,5-dihydro-2H-pyrrol-2- one
5- 1-Hydroxyl-1-methylethyl -2-propyl-imidazol-4-yl Carboxylic Acid Ethyl Ester
[5-(1-Hydroxyl-1-methylethyl)-2-propyl-imidazol-4-yl]carboxylic acid ethyl ester
